English | Español
Jamie Barrand | Dec 11, 2015

Baxalta receives FDA approval for von Willebrand disease treatment
Jamie Barrand | Dec 11, 2015

Merck presents Keytruda study results at American Society of Hematology meeting

Jamie Barrand | Dec 10, 2015

Two Biogen therapies prove effective for treating hemophilia
Jamie Barrand | Dec 10, 2015

Association of Black Cardiologists, PhRMA detail new treatments for heart disease, stroke patients
Jamie Barrand | Dec 10, 2015

Boehringer Ingelheim researchers test nintedanib on patients with severe lung disease
Jamie Barrand | Dec 10, 2015

FDA grants priority review to Pfizer cancer treatment
Jamie Barrand | Dec 8, 2015

Pfizer awards more than $4 million in grants for breast cancer research programs
Jamie Barrand | Dec 8, 2015

FDA approves Pfizer's new chewable ADHD treatment

Trending
+ Pharmaceuticals
Patient Daily | Jun 30, 2025

PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+ Pharmaceuticals
Patient Daily | Jun 25, 2025

Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’
+ Pharmaceuticals
Patient Daily | Jul 1, 2025

PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’